Allergan and its partner Perrigo Company have received US Food and Drug Administration (FDA) approval for their abbreviated new drug applications for three Mucinex equivalent products, cough medicines.

The products are: Mucinex DM Regular Strength (guaifenesin 600mg and dextromethorphan 30mg); Mucinex DM Maximum Strength (guaifenesin 1200 mg and dextromethorphan 60 mg); Mucinex Maximum Strength (guaifenesin 1200 mg). Mucinex Maximum Strength is an expectorant indicated to relieve chest congestion and thin and loosen mucus. Sales for the last twelve months were $73 million. Mucinex DM Regular and Maximum Strengths are expectorants indicated to control coughs and thin and loosen mucus. Mucinex DM Regular and Maximum Strengths sales for the last twelve months were $67 million and $104 million, respectively.

Perrigo will begin shipments of the products to its retail and wholesale customers in the US in time for the 2016 cough and cold season. These products will be packaged and marketed as store brands.

Source: Allergan